Zhejiang Sunflower Light Energy (300111) - Total Assets
Based on the latest financial reports, Zhejiang Sunflower Light Energy (300111) holds total assets worth CN¥969.22 Million CNY (≈ $141.83 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Zhejiang Sunflower Light Energy for net asset value and shareholders' equity analysis.
Zhejiang Sunflower Light Energy - Total Assets Trend (2007–2024)
This chart illustrates how Zhejiang Sunflower Light Energy's total assets have evolved over time, based on quarterly financial data.
Zhejiang Sunflower Light Energy - Asset Composition Analysis
Current Asset Composition (December 2024)
Zhejiang Sunflower Light Energy's total assets of CN¥969.22 Million consist of 78.9% current assets and 21.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 56.8% |
| Accounts Receivable | CN¥73.94 Million | 7.4% |
| Inventory | CN¥142.83 Million | 14.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥59.10 Million | 5.9% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how Zhejiang Sunflower Light Energy's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Zhejiang Sunflower Light Energy.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Sunflower Light Energy's current assets represent 78.9% of total assets in 2024, an increase from 77.7% in 2007.
- Cash Position: Cash and equivalents constituted 56.8% of total assets in 2024, up from 7.1% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 3.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 14.3% of total assets.
Zhejiang Sunflower Light Energy Competitors by Total Assets
Key competitors of Zhejiang Sunflower Light Energy based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Zhejiang Sunflower Light Energy - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.27 | 5.19 | 2.04 |
| Quick Ratio | 5.84 | 4.25 | 1.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥654.88 Million | CN¥689.70 Million | CN¥195.44 Million |
Zhejiang Sunflower Light Energy - Advanced Valuation Insights
This section examines the relationship between Zhejiang Sunflower Light Energy's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.50 |
| Latest Market Cap to Assets Ratio | 0.73 |
| Asset Growth Rate (YoY) | -19.6% |
| Total Assets | CN¥999.12 Million |
| Market Capitalization | $730.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Sunflower Light Energy's assets below their book value (0.73x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Zhejiang Sunflower Light Energy's assets decreased by 19.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Zhejiang Sunflower Light Energy (2007–2024)
The table below shows the annual total assets of Zhejiang Sunflower Light Energy from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥999.12 Million ≈ $146.20 Million |
-19.56% |
| 2023-12-31 | CN¥1.24 Billion ≈ $181.75 Million |
+101.55% |
| 2022-12-31 | CN¥616.25 Million ≈ $90.18 Million |
-2.44% |
| 2021-12-31 | CN¥631.63 Million ≈ $92.43 Million |
+11.90% |
| 2020-12-31 | CN¥564.44 Million ≈ $82.60 Million |
-18.67% |
| 2019-12-31 | CN¥694.03 Million ≈ $101.56 Million |
-52.35% |
| 2018-12-31 | CN¥1.46 Billion ≈ $213.11 Million |
-45.97% |
| 2017-12-31 | CN¥2.70 Billion ≈ $394.46 Million |
-3.86% |
| 2016-12-31 | CN¥2.80 Billion ≈ $410.28 Million |
-8.93% |
| 2015-12-31 | CN¥3.08 Billion ≈ $450.52 Million |
-2.38% |
| 2014-12-31 | CN¥3.15 Billion ≈ $461.51 Million |
+9.74% |
| 2013-12-31 | CN¥2.87 Billion ≈ $420.54 Million |
-5.39% |
| 2012-12-31 | CN¥3.04 Billion ≈ $444.47 Million |
-14.43% |
| 2011-12-31 | CN¥3.55 Billion ≈ $519.44 Million |
+26.27% |
| 2010-12-31 | CN¥2.81 Billion ≈ $411.37 Million |
+46.80% |
| 2009-12-31 | CN¥1.92 Billion ≈ $280.23 Million |
+19.34% |
| 2008-12-31 | CN¥1.60 Billion ≈ $234.81 Million |
+189.05% |
| 2007-12-31 | CN¥555.16 Million ≈ $81.24 Million |
-- |
About Zhejiang Sunflower Light Energy
Zhejiang Sunflower Great Health Co., Ltd. engages in the research, development, production, and sale of anti-infectious, cardiovascular, digestive system and other drugs in China and internationally. It offers clarithromycin API and tablets, anti-infective drugs used for nasopharyngeal infection, lower respiratory tract infection, skin and soft tissue infection, acute otitis media, Mycoplasma pne… Read more